Zobrazeno 1 - 10 of 232 pro vyhledávání: '"Byron J, Gajewski"'
1
Akademický článek
Using Bayesian hierarchical modeling for performance evaluation of clinical trial accrual for a cancer center
Autor: Xiaosong Shi, Dinesh Pal Mudaranthakam, Jo A. Wick, David Streeter, Jeffrey A. Thompson, Natalie R. Streeter, Tara L. Lin, Joseph Hines, II, Matthew S. Mayo, Byron J. Gajewski
Publikováno v: Contemporary Clinical Trials Communications, Vol 38, Iss , Pp 101281- (2024)
Introduction: Slow patient accrual in cancer clinical trials is always a concern. In 2021, the University of Kansas Comprehensive Cancer Center (KUCC), an NCI-designated comprehensive cancer center, implemented the Curated Cancer Clinical Outcomes Da
Externí odkaz: https://doaj.org/article/c8d834bc4d1745538693cf8d7aeec80e
Zobrazit plný text záznamu
2
Akademický článek
Conducting a bayesian multi-armed trial with response adaptive randomization for comparative effectiveness of medications for CSPN
Autor: Alexandra R. Brown, Byron J. Gajewski, Dinesh Pal Mudaranthakam, Mamatha Pasnoor, Mazen M. Dimachkie, Omar Jawdat, Laura Herbelin, Matthew S. Mayo, Richard J. Barohn
Publikováno v: Contemporary Clinical Trials Communications, Vol 36, Iss , Pp 101220- (2023)
Background: Response adaptive randomization is popular in adaptive trial designs, but the literature detailing its execution is lacking. These designs are desirable for patients/stakeholders, particularly in comparative effectiveness research, due to
Externí odkaz: https://doaj.org/article/b52e6d82e8a64ea2a96d8818dd50de39
Zobrazit plný text záznamu
3
Akademický článek
A novel Bayesian adaptive design incorporating both primary and secondary endpoints for randomized IIB chemoprevention study of women at increased risk for breast cancer
Autor: Byron J. Gajewski, Bruce F. Kimler, Devin C. Koestler, Dinesh Pal Mudaranthakam, Kate Young, Carol J. Fabian
Publikováno v: Trials, Vol 23, Iss 1, Pp 1-11 (2022)
Abstract Background Our randomized controlled clinical trial will explore the potential of bazedoxifene plus conjugated estrogen to modulate breast tissue-based risk biomarkers as a surrogate for breast cancer risk reduction. This paper investigates
Externí odkaz: https://doaj.org/article/59ae739e2a94408fb0db46be8e21c1f5
Zobrazit plný text záznamu
4
Akademický článek
Optimizing a Bayesian hierarchical adaptive platform trial design for stroke patients
Autor: Guangyi Gao, Byron J. Gajewski, Jo Wick, Jonathan Beall, Jeffrey L. Saver, Caitlyn Meinzer, the STEP-STONE Executive Committee
Publikováno v: Trials, Vol 23, Iss 1, Pp 1-15 (2022)
Abstract Background Platform trials are well-known for their ability to investigate multiple arms on heterogeneous patient populations and their flexibility to add/drop treatment arms due to efficacy/lack of efficacy. Because of their complexity, it
Externí odkaz: https://doaj.org/article/f9c6cbad423f4729be43844fc66eb060
Zobrazit plný text záznamu
5
Akademický článek
Unifying the analysis of continuous and categorical measures of weight loss and incorporating group effect: a secondary re-analysis of a large cluster randomized clinical trial using Bayesian approach
Autor: Fengming Tang, Christie A. Befort, Jo Wick, Byron J. Gajewski
Publikováno v: BMC Medical Research Methodology, Vol 22, Iss 1, Pp 1-10 (2022)
Abstract Background Although frequentist paradigm has been the predominant approach to clinical studies for decades, some limitations associated with the frequentist null hypothesis significance testing have been recognized. Bayesian approaches can p
Externí odkaz: https://doaj.org/article/e009e81a679e4748911c566390d1c06a
Zobrazit plný text záznamu
6
Akademický článek
Comparison of hierarchical EMAX and NDLM models in dose-response for early phase clinical trials
Autor: Xiaqing Huang, Byron J. Gajewski
Publikováno v: BMC Medical Research Methodology, Vol 20, Iss 1, Pp 1-13 (2020)
Abstract Background Phase II clinical trials primarily aim to find the optimal dose and investigate the relationship between dose and efficacy relative to standard of care (control). Therefore, before moving forward to a phase III confirmatory trial,
Externí odkaz: https://doaj.org/article/038e449200b943ac8722e35a2cf916c8
Zobrazit plný text záznamu
7
The value of a two-armed Bayesian response adaptive randomization trial
Autor: Byron J Gajewski, Susan E Carlson, Alexandra R Brown, Dinesh Pal Mudaranthakam, Elizabeth H Kerling, Christina J Valentine
Publikováno v: Journal of biopharmaceutical statistics. 33(1)
We investigate the value of a two-armed Bayesian response adaptive randomization (RAR) design to investigate early preterm birth rates of high versus low dose of docosahexaenoic acid during pregnancy. Unexpectedly, the COVID-19 pandemic forced recrui
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::37aae4b67ee3e7670bff3898d0a2d0a4
https://pubmed.ncbi.nlm.nih.gov/36411742
Zobrazit plný text záznamu
10
Akademický článek
Improving the efficiency of clinical trials by standardizing processes for Investigator Initiated Trials
Autor: Dinesh Pal Mudaranthakam, Milind A. Phadnis, Ron Krebill, Lauren Clark, Jo A. Wick, Jeffrey Thompson, John Keighley, Byron J. Gajewski, Devin C. Koestler, Matthew S. Mayo
Publikováno v: Contemporary Clinical Trials Communications, Vol 18, Iss , Pp 100579- (2020)
1. Abstract: Early phase clinical trials are the first step in testing new medications and therapeutics developed by clinical and biomedical investigators. These trials aim to find a safe dose of a newly targeted drug (phase I) or find out more about
Externí odkaz: https://doaj.org/article/3cc8b5b24ad24077bdcf70c6f17246dd
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje